Methods of diagnosis of colorectal cancer, compositions and methods of screening for modulators of colorectal cancer
AssigneesEos Biotechnology, Inc., Case Western Reserve University
InventorsDavid H. Mack, Sanford David Markowitz, Thomas Ried
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions that can be used for diagnosis and treatment of colorectal cancer. Also described herein are methods that can be used to identify modulators of colorectal cancer.
Claims51
A method of detecting a colorectal cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B.
A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
- (i) providing a biological sample from a patient undergoing the therapeutic treatment;
- and
- (ii) determining the level of a colorectal cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, thereby monitoring the efficacy of the therapy.
A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
- (i) providing a biological sample from a patient undergoing the therapeutic treatment;
- and
- (ii) determining the level of a colorectal cancer-associated antibody in the biological sample by contacting the biological sample with a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, wherein the polypeptide specifically binds to the colorectal cancer-associated antibody, thereby monitoring the efficacy of the therapy.
A method of monitoring the efficacy of a therapeutic treatment of colorectal cancer, the method comprising the steps of:
- (i) providing a biological sample from a patient undergoing the therapeutic treatment;
- and
- (ii) determining the level of a colorectal cancer-associated polypeptide in the biological sample by contacting the biological sample with an antibody, wherein the antibody specifically binds to a polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B, thereby monitoring the efficacy of the therapy.
An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Table 1, 1A or 1B.
An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Table 1, 1A or 1B.
A method of detecting antibodies specific to colorectal cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprises a sequence from Table 1, 1A or 1B.
A method for identifying a compound that modulates a colorectal cancer-associated polypeptide, the method comprising the steps of:
- (i) contacting the compound with a colorectal cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B;
- and
- (ii) determining the functional effect of the compound upon the polypeptide.
A drug screening assay comprising the steps of
- (i) administering a test compound to a mammal having colorectal cancer or a cell isolated therefrom;
- (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Table 1, 1A or 1B in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of colorectal cancer.
Dependencies are inferred from the claim text.